v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash Flows From Operating Activities    
Net loss $ (590,489) $ (587,259)
Non-cash items:    
Stock-based compensation expense 210,016 231,933
Depreciation expense 25
Amortization of ROU asset 642 641
Expenses allocated by Sanovas on behalf of Company 165,375 165,375
Changes in operating liabilities:    
Increase in accounts payable and accrued liabilities 104,757 1,257
Decrease in lease liability (474) (154)
Increase in accrued interest 960 960
Total adjustments 481,276 400,037
Net cash (used in) operating activities (109,213) (187,222)
Cash Flows From Financing Activities    
Proceeds from collection of stock subscription receivable 125,000 150,000
Proceeds from exercise of stock options and warrants
Advances from related parties, net (30,381) 34,873
Net cash provided by financing activities 94,619 184,873
Net (decrease) in cash (14,594) (2,349)
Cash at beginning of period 14,774 6,060
Cash at end of period 180 3,711
Supplemental Disclosure of Cash Flow information:    
Interest paid during the period
Income taxes paid during the period